Addressing human variability in next-generation human health risk assessments of environmental chemicals

Environmental Health Perspectives

Volumn 121, Issue 1, 2013, Pages 23-31

  Zeise, Lauren ^a   Bois, Frederic Y ^b   Chiu, Weihsueh A ^c   Hattis, Dale ^d   Rusyn, Ivan ^e   Guyton, Kathryn Z ^c  

^a CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY   (United States)

^b INSTITUT NATIONAL DE L ENVIRONNEMENT INDUSTRIEL ET DES RISQUES INERIS   (France)

^c U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^d CLARK UNIVERSITY   (United States)

^e University of North Carolina at Chapel Hill   (United States)

Author keywords

Environmental agents; Genetics; Human health risk assessment; Modeling; Omics technologies; Susceptible populations; Variability

Indexed keywords

1, 3 BUTADIENE; CYANOCOBALAMIN; ENVIRONMENTAL CHEMICAL; OZONE; PARACETAMOL; TRICHLOROETHYLENE; UNCLASSIFIED DRUG; XENOBIOTIC AGENT;

AIRBORNE PARTICLE; BREATHING RATE; CONCEPTUAL FRAMEWORK; CYTOTOXICITY; DECISION MAKING; DETOXIFICATION; DIETARY INTAKE; DOSE RESPONSE; ENVIRONMENTAL EXPOSURE; FLUID INTAKE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEALTH HAZARD; HUMAN; LIVER INJURY; MENTAL STRESS; METABOLISM; NEOPLASM; PHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; SOCIOBIOLOGY;

ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL HEALTH; ENVIRONMENTAL MONITORING; HUMANS; MODELS, THEORETICAL; RISK ASSESSMENT;

RODENTIA;

EID: 84872095490     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.1205687     Document Type: Review

References (108)

1. Allen BC, Hack CE, Clewell HJ. 2007. Use of Markov Chain Monte Carlo analysis with a physiologically-based pharmacokinetic model of methylmercury to estimate exposures in US women of childbearing age. Risk Anal 27(4):947-959.
2. Beal SL, Sheiner LB. 1982. Estimating population kinetics. Crit Rev Biomed Eng 8(3):195-222.
3. Bernillon P, Bois FY. 2000. Statistical issues in toxicokinetic modeling: a Bayesian perspective. Environ Health Perspect 108:883-893.
4. Bois FY. 2010. Physiologically based modelling and prediction of drug interactions. Basic Clin Pharmacol 106(3):154-161.
5. Bois FY, Compton-Quintana PJ. 1992. Sensitivity analysis of a new model of carcinogenesis. J Theor Biol 159(3):361-375.
6. Bois FY, Gelman A, Jiang J, Maszle DR, Zeise L, Alexeef G. 1996. Population toxicokinetics of tetrachloroethylene. Arch Toxicol 70(6):347-355.
7. Bois FY, Jamei M, Clewell HJ. 2010. PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals. Toxicology 278(3):256-267.
8. Bois FY, Krowech G, Zeise L. 1995. Modeling human interindividual variability in metabolism and risk: the example of 4-aminobiphenyl. Risk Anal 15(2):205-213.
9. Bois FY, Zeise L, Tozer TN. 1990. Precision and sensitivity of pharmacokinetic models for cancer risk assessment: tetrachloroethylene in mice, rats, and humans. Toxicol Appl Pharmacol 102(2):300-315.
10. Bradford BU, Lock EF, Kosyk O, Kim S, Uehara T, Harbourt D, et al. 2011. Interstrain differences in the liver effects of trichloroethylene in a multistrain panel of inbred mice. Toxicol Sci 120(1):206-217.
11. 1 in humans: a secondary analysis of existing data. Environ Health Perspect 116:1023-1026.
12. Burmaster DE, Murray DM. 1998. A trivariate distribution for the height, weight, and fat of adult men. Risk Anal 18(4):385-389.
13. Chen Y, Zhu J, Lum PY, Yang X, Pinto S, MacNeil DJ, et al. 2008. Variations in DNA elucidate molecular networks that cause disease. Nature 452(7186):429-435.
14. Chiu WA, Euling SY, Scott CS, Subramaniam RP. 2010. Approaches to advancing quantitative human health risk assessment of environmental chemicals in the post-genomic era. Toxicol Appl Pharmacol; doi.org/10.1016/j.taap.2010.03.019 [Online 29 March 2010].
15. Chiu WA, Okino MS, Evans MV. 2009. Characterizing uncertainty and population variability in the toxicokinetics of trichloroethylene and metabolites in mice, rats, and humans using an updated database, physiologically based pharmacokinetic (PBPK) model, and Bayesian approach. Toxicol Appl Pharmacol 241(1):36-60.
16. Collins FS, Gray GM, Bucher JR. 2008. Transforming environmental health protection. Science 319(5865):906-907.
17. Crump KS, Chen C, Chiu WA, Louis TA, Portier CJ, Subramaniam RP, et al. 2010. What role for biologically based dose-response models in estimating low-dose risk? Environ Health Perspect 118:585-588.
18. Csajka C, Verotta D. 2006. Pharmacokinetic-pharmacodynamic modelling: history and perspectives. J Pharmacokinet Pharmacodyn 33(3):227-279.
19. Dorne JL. 2010. Metabolism, variability and risk assessment. Toxicology 268(3):156-164.
20. Dumas ME, Wilder SP, Bihoreau MT, Barton RH, Fearnside JF, Argoud K, et al. 2007. Direct quantitative trait locus mapping of mammalian metabolic phenotypes in diabetic and normoglycemic rat models. Nat Genet 39(5):666-672.
21. Durbin R, Abecasis G, Altshuler D, Auton A, Brooks L, Gibbs R. 2010. A map of human genome variation from population-scale sequencing. Nature 467(7319):1061-1073.
22. Emilsson V, Tholeifsson G, Zhang B, Leonardson AS, Zink F, Zhu J, et al. 2008. Genetics of gene expression and its effect on disease. Nature 452(7186):423-428.
23. Gieger C, Geistlinger L, Altmaier E, de Angelis MH, Kronenberg F, Meitinger T, et al. 2008. Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum. PLoS Genet 4(11):e1000282; doi:10.1371/journal.pgen.1000282 [Online 28 November 2008].
24. Ginsberg G, Angle K, Guyton K, Sonawane B. 2011. Polymorphism in the DNA repair enzyme XRCC1: utility of current database and implications for human health risk assessment. Mutat Res 727(1-2):1-15.
25. Ginsberg G, Guyton K, Johns D, Schimek J, Angle K, Sonawane B. 2010. Genetic polymorphism in metabolism and host defense enzymes: implications for human health risk assessment. Crit Rev Toxicol 40(7):575-619.
26. Ginsberg G, Hattis D, Sonawane B. 2004. Incorporating pharmacokinetic differences between children and adults in assessing children's risks to environmental toxicants. Toxicol Appl Pharmacol 198(2):164-183.
27. Ginsberg G, Hattis D, Sonawane B, Russ A, Banati P, Kozlak M, et al. 2002. Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol Sci 66(2):185-200.
28. Ginsberg G, Neafsey P, Hattis D, Guyton KZ, Johns DO, Sonawane B. 2009a. Genetic polymorphism in paraoxonase 1 (PON1): Population distribution of PON1 activity. J Toxicol Environ Health B Crit Rev 12(5):473-507.
29. Ginsberg G, Smolenski S, Hattis D, Guyton KZ, Johns DO, Sonawane B. 2009b. Genetic polymorphism in glutathione transferases (GST): population distribution of GSTM1, T1, and P1 conjugating activity. J Toxicol Environ Health B Crit Rev 12(5):389-439.
30. Ginsberg G, Smolenski S, Neafsey P, Hattis D, Walker K, Guyton KZ, et al. 2009c. The influence of genetic polymorphisms on population variability in six xenobiotic-metabolizing enzymes. J Toxicol Environ Health B Crit Rev 12(5):307-333.
31. Giorgino T, D'Abramo M, Gervasio F, De Fabritiis G. 2010. Exploring the kinetics of drug binding to the hERG channel through large-scale simulations [Abstract]. In: Proceedings of the 2010 Virtual Physiological Human Conference, 30 September-1 October 2010, pp. 248-250. Bruxelles, Belgium. Available: http://www.vph-noe.eu/vph-repository/doc_download/204-book-of-abstracts-for-vph20107 [accessed 8 June 2012].
32. Guo Y, Lu P, Farrell E, Zhang X, Weller P, Monshouwer M, et al. 2007. In silico and in vitro pharmacogenetic analysis in mice. Proc Natl Acad Sci USA 104(45):17735-17740.
33. Guo Y, Weller P, Farrell E, Cheung P, Fitch B, Clark D, et al. 2006. In silico pharmacogenetics of warfarin metabolism. Nat Biotechnol 24(5):531-536.
34. Guyton KZ, Kyle AD, Aubrecht J, Cogliano VJ, Eastmond DA, Jackson M, et al. 2009. Improving prediction of chemical carcinogenicity by considering multiple mechanisms and applying toxicogenomic approaches. Mutat Res Rev Mutat Res 681(2-3):230-240.
35. Hack CE. 2006. Bayesian analysis of physiologically based toxicokinetic and toxicodynamic models. Toxicology 221(2-3):241-248.
36. Hamade AK, Misra V, Rabold R, Tankersley CG. 2010. Age-related changes in cardiac and respiratory adaptation to acute ozone and carbon black exposures: interstrain variation in mice. Inhal Toxicol 22(supp 2):84-94.
37. Harrill AH, Ross PK, Gatti DM, Threadgill DW, Rusyn I. 2009a. Population-based discovery of toxicogenomics biomarkers for hepatotoxicity using a laboratory strain diversity panel. Toxicol Sci 110(1):235-243.
38. Harrill AH, Watkins PB, Su S, Ross PK, Harbourt DE, Stylianou IM, et al. 2009b. Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans. Genome Res 19(9):1507-1515.
39. Hattis D. 1997. Human variability in susceptibility: how big, how often, for what responses to what agents? Environ Toxicol Pharmacol 4(3-4):195-208.
40. Hattis D, Baird S, Goble R. 2002. A straw man proposal for a quantitative definition of the RfD. Drug Chem Toxicol 25(4):403-436.
41. Hattis D, Ginsberg G, Sonawane B, Smolenski S, Russ A, Kozlak M, et al. 2003. Differences in pharmacokinetics between children and adults: II. Childrens variability in drug elimination half-lives and in some parameters needed for physiologically-based pharmacokinetic modeling. Risk Anal 23(1):117-142.
42. Hattis D, Russ A, Goble R, Banati P, Chu M. 2001. Human interindividual variability in susceptibility to airborne particles. Risk Anal 21(4):585-599.
43. Hernandez ML, Lay JC, Harris B, Esther CR Jr, Brickey WJ, Bromberg PA, et al. 2010. Atopic asthmatic subjects but not atopic subjects without asthma have enhanced inflammatory response to ozone. J Allergy Clin Immunol 126(3):537-544.e1; doi:10.1016/j.jaci.2010.06.043.
44. Holloway JW, Savarimuthu Francis S, Fong KM, Yang IA. 2012. Genomics and the respiratory effects of air pollution exposure. Respirology 17(4):590-600.
45. Huang RS, Johnatty SE, Gamazon ER, Im HK, Ziliak D, Duan S, et al. 2011. Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res 17(16):5490-5500.
46. Hucka M, Finney A, Sauro HM, Bolouri H, Doyle JC, Kitano H, et al. 2003. The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models. Bioinformatics 19(4):524-531.
47. Hutter CM, Chang-Claude J, Slattery ML, Pflugeisen BM, Lin Y, Duggan D, et al. 2012. Characterization of gene-environment interactions for colorectal cancer susceptibility loci. Cancer Res 72(8):2036-2044.
48. Illig T, Gieger C, Zhai G, Römisch-Margl W, Wang-Sattler R, Prehn C, et al. 2010. A genome-wide perspective of genetic variation in human metabolism. Nat Genet 42(2):137-141.
49. International Programme for Chemical Safety. 2001. Guidance Document for the Use of Data in Development of Chemical-Specific Adjustment Factors (CSAFs) for Interspecies Differences and Human Variability in Dose/Concentration-Response Assessment. WHO/PCS/01.4. Available: http://www.who.int/ipcs/publications/methods/harmonization/en/csafs_guidance_doc.pdf [accessed 8 June 2012].
50. Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, Rostami-Hodjegan A. 2009. The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol 5(2):211-223.
51. Jia X, Song X, Shima M, Tamura K, Deng F, Guo X. 2011. Acute effect of ambient ozone on heart rate variability in healthy elderly subjects. J Expo Sci Environ Epidemiol 21(5):541-547.
52. Johanson G, Jonsson F, Bois F. 1999. Development of new technique for risk assessment using physiologically based toxicokinetic models. Am J Ind Med 1:101-103.
53. Jonsson F, Jonsson EN, Bois FY, Marshall S. 2007. The application of a Bayesian approach to the analysis of a complex, mechanistically based model. J Biopharm Stat 17(1):65-92.
54. Judson RS, Kavlock RJ, Setzer RW, Hubal EA, Martin MT, Knudsen TB, et al. 2011. Estimating toxicity-related biological pathway altering doses for high-throughput chemical risk assessment. Chem Res Toxicol 24(4):451-462.
55. Kedderis G. 1997. Extrapolation of in vitro enzyme induction data to humans in vivo. Chem Biol Interact 107(1-2):109-121.
56. Khoury MJ, Bowen MS, Burke W, Coates RJ, Dowling NF, Evans JP, et al. 2011. Current priorities for public health practice in addressing the role of human genomics in improving population health. Am J Prev Med 40(4):486-493.
57. Kleeberger SR, Levitt RC, Zhang LY, Longphre M, Harkema J, Jedlicka A, et al. 1997. Linkage analysis of susceptibility to ozone-induced lung inflammation in inbred mice. Nat Genet 17:475-478.
58. Koturbash I, Scherhag A, Sorrentino J, Sexton K, Bodnar W, Swenberg JA, et al. 2011. Epigenetic mechanisms of mouse interstrain variability in genotoxicity of the environmental toxicant 1,3-butadiene. Toxicol Sci 122(2):448-456.
59. La Thangue NB, Kerr DJ. 2011. Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol 8(10):587-596.
60. Lock EF, Abdo N, Huang R, Xia M, Kosyk O, O'Shea SH, et al. 2012. Quantitative high-throughput screening for chemical toxicity in a population-based in vitro model. Toxicol Sci 126(2):578-588.
61. Luke NS, Devito MJ, Shah I, El-Masri HA. 2010a. Development of a quantitative model of pregnane X receptor (PXR) mediated xenobiotic metabolizing enzyme induction. Bull Math Biol 72(7):1799-1819.
62. Luke NS, Sams R II, DeVito MJ, Conolly RB, El-Masri HA. 2010b. Development of a quantitative model incorporating key events in a hepatotoxic mode of action to predict tumor incidence. Toxicol Sci 115(1):253-266.
63. Manolio TA. 2010. Genomewide association studies and assessment of the risk of disease. N Engl J Med 363(2):166-176.
64. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, et al. 2009. Finding the missing heritability of complex diseases. Nature 461(7265):747-753.
65. Martin MT, Dix DJ, Judson RS, Kavlock RJ, Reif DM, Richard AM, et al. 2010. Impact of environmental chemicals on key transcription regulators and correlation to toxicity end points within EPA's ToxCast program. Chem Res Toxicol 23(3):578-590.
66. McLanahan ED, Andersen ME, Fisher JW. 2008. A biologically based dose-response model for dietary iodide and the hypothalamic-pituitary-thyroid axis in the adult rat: evaluation of iodide deficiency. Toxicol Sci 102(2):241-253.
67. Mortensen HM, Euling SY. 2011. Integrating mechanistic and polymorphism data to characterize human genetic susceptibility for environmental chemical risk assessment in the 21st century. Toxicol Appl Pharmacol; doi:10.1016/j.taap.2011.01.015 [Online 1 February 2011].
68. Neafsey P, Ginsberg G, Hattis D, Johns DO, Guyton KZ, Sonawane B. 2009a. Genetic polymorphism in CYP2E1: Population distribution of CYP2E1 activity. J Toxicol Environ Health B Crit Rev 12(5):362-388.
69. Neafsey P, Ginsberg G, Hattis D, Sonawane B. 2009b. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity. J Toxicol Environ Health B Crit Rev 12(5):334-361.
70. Nong A, Tan YM, Krolski ME, Wang J, Lunchick C, Conolly RB, et al. 2008. Bayesian calibration of a physiologically based pharmacokinetic/pharmacodynamic model of carbaryl cholinesterase inhibition. J Toxicol Environ Health A 71(20):1363-1381.
71. NRC (National Research Council). 2007. Toxicity Testing in the 21st Century: A Vision and a Strategy. Washington, DC:National Academies Press. Available: http://www.nap.edu/catalog.php?record_id=11970 [accessed 8 June 2012].
72. NRC (National Research Council). 2009. Science and Decisions: Advancing Risk Assessment. Washington, DC:National Academies Press. Available: http://www.nap.edu/catalog.php?record_id=12209 [accessed 8 June 2012].
73. O'Shea SH, Schwarz J, Kosyk O, Ross PK, Ha MJ, Wright FA, et al. 2011. In vitro screening for population variability in chemical toxicity. Toxicol Sci 119(2):398-407.
74. Patel CJ, Bhattacharya J, Butte AJ. 2010. An Environment-Wide Association Study (EWAS) on type 2 diabetes mellitus. PLoS ONE 5(5):e10746; doi:10.1371/journal.pone.0010746 [Online 20 May 2010].
75. Peters EJ, Motsinger-Reif A, Havener TM, Everitt L, Hardison NE, Watson VG, et al. 2011. Pharmacogenomic characterization of US FDA-approved cytotoxic drugs. Pharmacogenomics 12(10):1407-1415.
76. Phillips EJ, Mallal SA. 2010. Pharmacogenetics of drug hypersensitivity. Pharmacogenomics 11(7):973-987.
77. Portier CJ, Kaplan NL. 1989. Variability of safe dose estimates when using complicated models of the carcinogenic process. A case study: methylene chloride. Fundam Appl Toxicol 13(3):533-544.
78. Prows DR, Shertzer HG, Daly MJ, Sidman CL, Leikauf GD. 1997. Genetic analysis of ozone-induced acute lung injury in sensitive and resistant strains of mice. Nat Genet 17:471-474.
79. Rappaport SM, Smith MT. 2010. Epidemiology. Environment and disease risks. Science 330(6003):460-461.
80. Reif DM, Martin MT, Tan SW, Houck KA, Judson RS, Richard AM, et al. 2010. Endocrine profiling and prioritization of environmental chemicals using ToxCast data. Environ Health Perspect 118:1714-1720.
81. Rosenberg NA, Huang L, Jewett EM, Szpiech ZA, Jankovic I, Boehnke M. 2010. Genome-wide association studies in diverse populations. Nat Rev Genet 11(5):356-366.
82. Rotroff DM, Wetmore BA, Dix DJ, Ferguson SS, Clewell HJ, Houck KA, et al. 2010. Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening. Toxicol Sci 117(2):348-358.
83. Roy AC, Loke DF, Saha N, Viegas OA, Tay JS, Ratnam SS. 1994. Interrelationships of serum paraoxonase, serum lipids and apolipoproteins in normal pregnancy. A longitudinal study. Gynecol Obstet Invest 38(1):10-13.
84. Rusyn I, Gatti DM, Wiltshire T, Wiltshire T, Kleeberger SR, Threadgill DW. 2010. Toxicogenetics: population-based testing of drug and chemical safety in mouse models. Pharmacogenomics 11(8):1127-1136.
85. Sadiq SK, Wright DW, Kenway OA, Coveney PV. 2010. Accurate ensemble molecular dynamics binding free energy ranking of multidrug-resistant HIV-1 proteases. J Chem Inf Model 50(5):890-905.
86. Schadt EE. 2009. Molecular networks as sensors and drivers of common human diseases. Nature 461(7261):218-223.
87. Schadt EE, Björkegren JL. 2012. NEW: network-enabled wisdom in biology, medicine, and health care. Sci Transl Med 4(115):115rv111; doi:10.1126/scitranslmed.3002132 [Online 4 January 2012].
88. Schuster P. 2008. Modeling in biological chemistry. From biochemical kinetics to systems biology. Monatshefte fur Chemie / Chemical Monthly 139(4):427-446.
89. Spear RC, Bois FY. 1994. Parameter variability and the interpretation of physiologically based pharmacokinetic modeling results. Environ Health Perspect 11:61-66.
90. Suhre K, Shin SY, Petersen AK, Mohney RP, Meredith D, Wägele B, et al. 2011. Human metabolic individuality in biomedical and pharmaceutical research. Nature 477(7362):54-60.
91. Thompson CM, Johns DO, Sonawane B, Barton HA, Hattis D, Tardif R, et al. 2009. Database for physiologically based pharmacokinetic (PBPK) modeling: physiological data for healthy and health-impaired elderly. J Toxicol Environ Health B Crit Rev 12(1):1-24.
92. U.S. EPA (U.S. Environmental Protection Agency). 1998. Toxicological Review of Beryllium and Compounds (CAS No.7440-41-7) in Support of Summary Information on the Integrated Risk Information System (IRIS). EPA/635/R-98/008. Washington, DC:U.S. EPA. Available: http://www.epa.gov/iris/toxreviews/0012tr.pdf [accessed 8 June 2012].
93. U.S. EPA (U.S. Environmental Protection Agency). 2002. Health Assessment of 1,3-Butadiene. EPA/600/P-98/001F. Washington, DC:U.S. EPA, Office of Research and Development, National Center for Environmental Assessment. Available: http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=54499 [accessed 8 June 2012].
94. U.S. EPA (U.S. Environmental Protection Agency). 2003. EPA Assessment of Risks from Radon in Homes. EPA/402/R-03/003. Washington, DC:U.S. EPA. Available: http://www.epa.gov/radiation/docs/assessment/402-r-03-003.pdf [accessed 8 June 2012].
95. U.S. EPA (U.S. Environmental Protection Agency). 2006. Air Quality Criteria for Ozone and Related Photochemical Oxidants. EPA/600/R-05/004aF-cF. Washington, DC:U.S. EPA. Available: http://cfpub.epa.gov/ncea/isa/recordisplay.cfm?deid=149923 [accessed 15 June 2012].
96. U.S. EPA (U.S. Environmental Protection Agency). 2007. Framework for Assessing the Public Health Impacts of Risk Management Decisions. Washington, DC:U.S. EPA, Office of Research and Development.
97. U.S. EPA (U.S. Environmental Protection Agency). 2011. Toxicological Review of Trichloroethylene (CASRN 79-01-6) in Support of Summary Information on the Integrated Risk Information System (IRIS). EPA/635/R-09/011F. Washington, DC:U.S. EPA. Available: http://www.epa.gov/iris/supdocs/0199index.html [accessed 8 June 2012].
98. Wakefield J. 1996. Bayesian individualization via sampling-based methods. J Pharmacokinet Biopharm 24(1):103-131.
99. Walker K, Ginsberg G, Hattis D, Johns D, Guyton KZ, Sonawane B. 2009. Genetic polymorphism in N-acetyltransferase (NAT): population distribution of NAT1 and NAT2 activity. J Toxicol Environ Health B Crit Rev 12(5-6):440-472.
100. Watson VG, Motsinger-Reif A, Hardison NE, Peters EJ, Havener TM, Everitt L, et al. 2011. Identification and replication of loci involved in camptothecin-induced cytotoxicity using CEPH pedigrees. PloS one 6(5):e17561; doi:10.1371/journal.pone.0017561 [Online 5 May 2011].
101. Welsh M, Mangravite L, Medina MW, Tantisira K, Zhang W, Huang RS, et al. 2009. Pharmacogenomic discovery using cell-based models. Pharmacol Rev 61(4):413-429.
102. Wild CP. 2005. Complementing the genome with an "exposome:" the outstanding challenge of environmental exposure measurement in molecular epidemiology. Cancer Epidemiol Biomarkers Prev 14(8):1847-1850.
103. Willmann S, Höhn K, Edginton A, Sevestre M, Solodenko J, Weiss W, et al. 2007. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn 34(3):401-431.
104. Wood AM, Harrison RM, Semple S, Ayres JG, Stockley RA. 2010. Outdoor air pollution is associated with rapid decline of lung function in a-1-antitrypsin deficiency. Occup Environ Med 67(8):556-561.
105. Woodruff TJ, Zeise L, Axelrad DA, Guyton KZ, Janssen S, Miller M, et al. 2008. Meeting report: Moving upstream-evaluating adverse upstream end points for improved risk assessment and decision-making. Environ Health Perspect 116:1568-1575.
106. Xia M, Huang R, Witt KL, Southall N, Fostel J, Cho MH, et al. 2008. Compound cytotoxicity profiling using quantitative high-throughput screening. Environ Health Perspect 116:284-291.
107. Xia MH, Huang RL, Guo V, Southall N, Cho MH, Inglese J, et al. 2009. Identification of compounds that potentiate CREB signaling as possible enhancers of long-term memory. Proc Natl Acad Sci USA 106(7):2412-2417.
108. Zhu H, Rusyn I, Richard A, Tropsha A. 2008. Use of cell viability assay data improves the prediction accuracy of conventional quantitative structure-activity relationship models of animal carcinogenicity. Environ Health Perspect 116:506-513.